Insensitivity to scope in contingent valuation studies: reason for dismissal of valuations?
- PMID: 22963163
- DOI: 10.1007/BF03261874
Insensitivity to scope in contingent valuation studies: reason for dismissal of valuations?
Abstract
Background: The credibility of contingent valuation studies has been questioned because of the potential occurrence of scope insensitivity, i.e. that respondents do not react to higher quantities or qualities of a good.
Objective: The aim of this study was to examine the extent of scope insensitivity and to assess the relevance of potential explanations that may help to shed light on how to appropriately handle this problem in contingent valuation studies.
Methods: We surveyed a sample of 2004 men invited for cardiovascular disease screening. Each respondent had three contingent valuation tasks from which their sensitivity to larger risk reductions (test 1) and to change in travel costs associated with participation (test 2) could be assessed. Participants were surveyed while waiting for their screening session. Non-participants were surveyed by postal questionnaire.
Results: The sample was overall found to be sensitive to scope, testing at the conventional sample-mean level. At the individual respondent level, however, more than half of the respondents failed the tests. Potential determinants for failing the tests were examined in alternative regression models but few consistent relationships were identified. One exception was the influence of more detailed information, which was positively associated with willingness to pay and negatively associated with scope sensitivity.
Conclusion: Possible explanations for scope insensitivity are discussed; if cognitive limitations, emotional load and mental budgeting explain scope insensitivity there are grounds for rejecting valuations, whereas other factors such as the alternative theoretical framework of regret theory may render insensitivity to scope a result of rational thinking. It is concluded that future contingent valuation studies should focus more on extracting the underlying motives for the stated preferences in order to appropriately deal with responses that are seemingly irrational, and which may lead to imprecise welfare estimates.
Comment in
-
Insensitivity to scope in contingent valuation studies: new direction for an old problem.Appl Health Econ Health Policy. 2012 Nov 1;10(6):361-3. doi: 10.1007/BF03261871. Appl Health Econ Health Policy. 2012. PMID: 22974467 No abstract available.
Similar articles
-
Insensitivity to scope in contingent valuation studies: new direction for an old problem.Appl Health Econ Health Policy. 2012 Nov 1;10(6):361-3. doi: 10.1007/BF03261871. Appl Health Econ Health Policy. 2012. PMID: 22974467 No abstract available.
-
Scope and scale insensitivities in a contingent valuation study of risk reductions.Health Policy. 2001 Aug;57(2):141-53. doi: 10.1016/s0168-8510(01)00117-8. Health Policy. 2001. PMID: 11395179
-
A comparison of two methods for eliciting contingent valuations of colorectal cancer screening.J Health Econ. 2003 Jul;22(4):555-74. doi: 10.1016/S0167-6296(03)00006-7. J Health Econ. 2003. PMID: 12842315
-
When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care.Med Decis Making. 1996 Jul-Sep;16(3):288-99. doi: 10.1177/0272989X9601600314. Med Decis Making. 1996. PMID: 8818128 Review.
-
Aiding priority setting in health care: is there a role for the contingent valuation method?Health Econ. 1997 Nov-Dec;6(6):603-12. doi: 10.1002/(sici)1099-1050(199711)6:6<603::aid-hec285>3.0.co;2-2. Health Econ. 1997. PMID: 9466142 Review.
Cited by
-
The impact of behavioural risk reduction interventions on willingness to pay to avoid sexually transmitted infections: a stated preference study of justice-involved youth.Appl Econ. 2017;49(56):5673-5685. doi: 10.1080/00036846.2017.1332744. Epub 2017 Jun 5. Appl Econ. 2017. PMID: 32753764 Free PMC article.
-
The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease.Pharmacoeconomics. 2025 Jun;43(6):677-689. doi: 10.1007/s40273-025-01482-3. Epub 2025 Mar 29. Pharmacoeconomics. 2025. PMID: 40156683 Free PMC article.
-
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks.Eur J Health Econ. 2023 Aug;24(6):967-986. doi: 10.1007/s10198-022-01527-w. Epub 2022 Sep 28. Eur J Health Econ. 2023. PMID: 36169765 Free PMC article.
-
Do Non-participants at Screening have a Different Threshold for an Acceptable Benefit-Harm Ratio than Participants? Results of a Discrete Choice Experiment.Patient. 2019 Oct;12(5):491-501. doi: 10.1007/s40271-019-00364-z. Patient. 2019. PMID: 31165400
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources